38 results on '"Resnati, Chiara"'
Search Results
2. Doravirine plus Integrase Strand Transfer Inhibitors as a two-drugs treatment-switch strategy in PLWH: the real-life DORINI multicentric cohort study
3. Identification of Drugs Acting as Perpetrators in Common Drug Interactions in a Cohort of Geriatric Patients from Southern Italy and Analysis of the Gene Polymorphisms That Affect Their Interacting Potential
4. Uptake of HCV treatment in HIV/HCV coinfected patients across europe in the era of direct-acting antivirals
5. Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data
6. Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals
7. Correlation between inner retinal layer thickness and cognitive function in HIV: new insights from an exploratory study
8. Dolutegravir and metformin: a clinically relevant or just a pharmacokinetic interaction?
9. Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF
10. Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient
11. Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens
12. When the absence of an interaction can become clinically relevant
13. Abacavir-induced liver toxicity
14. The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir
15. Toxicovigilance during COVID-19: attention to poisoning related to disinfection
16. Binding motif of ebselen in solution: Chalcogen and hydrogen bonds team up
17. Binding motif of ebselen in solution: chalcogen and hydrogen bonds team up
18. Prolonged inductive effect of rifampicin on linezolid exposure
19. IMPATTO DI COBICISTAT SU DURATA ETOLLERABILITA� DI REGIMI ANTIRETROVIRALICONTENENTI TENOFOVIR DIPROXIL FUMARATO
20. Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice.
21. Abacavir-induced liver toxicity
22. Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice
23. Dolutegravir and metformin
24. Generics for the Treatment of Hepatitis C in Monoinfected And HIV-Coinfected Patients: Pros and Cons
25. The Relevance of Drug–drug Interactions in Clinical Practice: The Case of Concomitant Boosted Protease Inhibitors plus Alpha-1 Blocker Administration
26. Effect of Legal Status on the Early Treatment Outcomes of Migrants Beginning Combined Antiretroviral Therapy at an Outpatient Clinic in Milan, Italy
27. Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors
28. Elvitegravir/cobicistat-associated toxic optical neuropathy in an HIV-infected patient: a call for caution?
29. Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient
30. Comparison of the Pharmacokinetics of Raltegravir Given at 2 Doses of 400 mg by Swallowing Versus One Dose of 800 mg by Chewing in Healthy Volunteers
31. Changes in the Incidence of Severe Thrombocytopenia and Its Predisposing Conditions in HIV-Infected Patients Since the Introduction of Highly Active Antiretroviral Therapy
32. Generics for the Treatment of Hepatitis C in Monoinfected and HIV-coinfected Patients: Pros and Cons.
33. The Relevance of Drug–drug Interactions in Clinical Practice: The Case of Concomitant Boosted Protease Inhibitors plus Alpha-1 Blocker Administration
34. Elvitegravir/Cobicistat-Associated Toxic Optical Neuropathy in an HIV-Infected Patient: A Call for Caution?
35. Doravirine Plus Integrase Strand Transfer Inhibitors as a 2-Drug Treatment-Switch Strategy in People Living with HIV: The Real-Life DORINI Multicentric Cohort Study.
36. Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF.
37. Effect of Legal Status on the Early Treatment Outcomes of Migrants Beginning Combined Antiretroviral Therapy at an Outpatient Clinic in Milan, Italy.
38. Changes in the incidence of severe thrombocytopenia and its predisposing conditions in HIV-infected patients since the introduction of highly active antiretroviral therapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.